Thus, through the promotion of anti-cancer immunity through multiple parallel pathways, activation of NRF2 by electrophilic KRASG12C-inhibitors positively contributes to the clinical efficacy of these anti-cancer drugs. This evidence concerns the gene NFE2L2 and cancer.